Barzolvolimab, an investigational immune therapy for chronic spontaneous urticaria, produced what one analyst described as the best efficacy results to date for the condition. The data, released by Celldex, showed substantial improvement in patients with persistent skin hives that often resist existing treatments.
However, the trial also recorded two cases of life-threatening anaphylaxis among treated patients. Those serious allergic reactions cast a shadow over the efficacy signal and triggered a sharp decline in Celldex's stock, as investors weighed the drug's promise against its potential safety risks.
Chronic spontaneous urticaria is marked by recurring itching and welts without an identifiable trigger. If the safety concerns can be resolved, barzolvolimab could become a significant treatment option, but the anaphylaxis cases are likely to draw close scrutiny from regulators and prescribing physicians.